Skip to main content

Table 1 Main clinical characteristics of the included studies

From: Effect of regional versus general anesthesia on recurrence of non-muscle invasive bladder cancer: a systematic review and meta-analysis of eight retrospective cohort studies

First Author

Year

Country

Stage

Study design

Total

RA

GA

Follow-up

Agents

Number

Age

Gender(M/F)

Agents

Number

Age

Gender(M/F)

(months)

Cheng Luo

2020

China

NMIBC

Retrospective single center

302

Marcaine

182

60a

141/41

Propofol, Remifentanil Sevoflurane

120

60a

98/22

33.5

Dale Jang

2016

Korea

T1-T2

Retrospective single center

161

Bupivacaine, Lidocaine

137

62.4 ± 10.8

107/30

Propofol, Etomidate Vecuronium, Rocuronium

24

67.5 ± 9.0

17/7

60

Ruifeng Xue

2022

China

NMIBC

Retrospective single center

528

Bupivacaine, Lidocaine, Ropivacaine

264

56.62 ± 13.809

239/25

Cis-atracurium, Fentanyl, Propofol, Remifentanil, Sevoflurane

264

58.54 ± 11.968

229/35

36

Sang Won Lee

2022

Korea

NMIBC

Retrospective single center

1164

NA

582

66.75 ± 6.09

460/122

NA

582

66.50 ± 6.06

460/122

52.6

Tingting Wang

2019

China

NMIBC

Retrospective single center

388

Bupivacaine Midazolam

136

69.27 ± 13.00

207/45

Propofol, Remifentanil, Rocuronium

252

62.09 ± 9.00

100/36

35.6

Woo-Jong Choi

2017

Korea

NMIBC

Retrospective single center

690

Bupivacaine, Midazolam

534

62 ± 12

436/98

Sevoflurane, Thiopental, Rocuronium, Atracurium, Nitrous oxide

156

61 ± 13

124/32

35

Yuri Koumpan

2018

Canada

NMIBC

Retrospective single center

231

NA

135

71.72 ± 10.57

109/26

NA

96

65.45 ± 10.86

77/19

65

Yuto Baba

2021

Japan

NMIBC

Retrospective multicenter

300

Bupivacaine

147

75b

115/32

Fentanyl, Propofol, Sevoflurane

153

75b

129/24

46.5

  1. NMIBC non-muscle invasive bladder cancer, RA regional anesthesia, GA general anesthesia, M/F male/female, NA not available
  2. aRA: ≥ 60:114, < 60:68; GA: ≥ 60:80, < 60:40; bRA: ≥ 75:37, < 75:110;GA: ≥ 75:64, < 75: 89